CreatorsPublishersAdvertisers
View more in
Cancer

Dr. Ready on Selecting Between Frontline Atezolizumab and Durvalumab in ES-SCLC

onclive.com
 2021-09-07

Neal E. Ready, MD, PhD, discusses selecting between frontline chemotherapy plus atezolizumab or durvalumab in extensive-stage small cell lung cancer. Neal E. Ready, MD, PhD, head and neck oncologist, medical oncologist, Duke Health, professor of medicine, member of the Duke Cancer Institute, Duke University School of Medicine, discusses selecting between frontline chemotherapy plus atezolizumab (Tecentriq) or durvalumab (Imfinzi) in extensive-stage small cell lung cancer (ES-SCLC).

www.onclive.com

Comments / 0

Comments / 0